Assessing Individual Risk for Prostate Cancer
- 20 August 2007
- journal article
- genitourinary cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (24) , 3582-3588
- https://doi.org/10.1200/jco.2007.10.6450
Abstract
Purpose: To construct a clinical nomogram instrument to estimate individual risk for having prostate cancer (PC) for patients undergoing prostate specific antigen (PSA) screening, using all risk factors known for PC. Patients and Methods: We conducted a cross-sectional study of 3,108 men who underwent a prostate biopsy, including a subset of 408 volunteers with normal PSA levels. Factors including age, family history of PC (FHPC), ethnicity, urinary symptoms, PSA, free:total PSA ratio, and digital rectal examination (DRE) were incorporated in the model. A nomogram was constructed to assess risk for any and high-grade PC (Gleason score ≥ 7). Results: Of the 3,108 men, 1,304 (42.0%) were found to have PC. Among the 408 men with a normal PSA (< 4.0 ng/mL), 99 (24.3%) had PC. All risk factors were important predictors for PC by multivariate analysis (P, .01 to .0001). The area under the curve (AUC) for the nomogram in predicting cancer, which included age, ethnicity, FHPC, urinary symptoms, free:total PSA ratio, PSA, and DRE, was 0.74 (95% CI, 0.71 to 0.81) and 0.77 (95% CI, 0.74 to 0.81) for high-grade cancer. This was significantly greater than the AUC that considered using the conventional screening method of PSA and DRE only (0.62; 95% CI, 0.58 to 0.66 for any cancer; 0.69; 95% CI, 0.65 to 0.73 for high-grade cancer). From receiver operating characteristic analysis, risk factors including age, ethnicity, FHPC, symptoms, and free:total PSA ratio contributed significantly more predictive information than PSA and DRE. Conclusion: In a PC screening program, it is important to consider age, family history of PC, ethnicity, urinary voiding symptoms, and free:total PSA ratio, in addition to PSA and DRE.Keywords
This publication has 28 references indexed in Scilit:
- A Novel Serum Marker, Total Prostate Secretory Protein of 94 Amino Acids, Improves Prostate Cancer Detection and Helps Identify High Grade Cancers at DiagnosisJournal of Urology, 2006
- Making Sense of Prostate Specific Antigen: Improving its Predictive Value in Patients Undergoing Prostate BiopsyJournal of Urology, 2006
- The Use of Genetic Markers to Determine Risk for Prostate Cancer at Prostate BiopsyClinical Cancer Research, 2005
- DEVELOPMENT AND VALIDATION OF A NOMOGRAM PREDICTING THE OUTCOME OF PROSTATE BIOPSY BASED ON PATIENT AGE, DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE SPECIFIC ANTIGENJournal of Urology, 2005
- VALIDATION OF A NOMOGRAM FOR PREDICTING POSITIVE REPEAT BIOPSY FOR PROSTATE CANCERJournal of Urology, 2005
- Variation in patterns of practice in diagnosing screen‐detected prostate cancerBJU International, 2004
- A Nomogram For Predicting a Positive Repeat Prostate Biopsy in Patients With a Previous Negative Biopsy SessionJournal of Urology, 2003
- Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer DetectionJournal of Clinical Oncology, 2003
- Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant managementCancer, 2001
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987